Related Experiment Video
Updated: May 2, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Factors Associated With Telehealth Buprenorphine Initiation
Objective:
Telehealth expanded buprenorphine access for opioid use disorder (OUD) after COVID-19 federal flexibilities permitted telehealth initiation. Limited evidence exists comparing telehealth and in-person buprenorphine initiation. This study examines correlates of telehealth versus in-person buprenorphine initiation among adults with OUD.
Methods:
We conducted a retrospective, cross-sectional analysis using the Integrated Humana Medical and Pharmacy dataset, including commercial, Medicaid, Medicare Advantage (MAPD), and Medicare Part D prescription drug plans (PDP). Adults with newly diagnosed OUD who initiated buprenorphine between March 17, 2020, and December 31, 2023, with no prior use in the preceding 180 days, were included. Correlates of telehealth initiation were identified using the Least Absolute Shrinkage and Selection Operator-penalized logistic regression.
Results:
Among 4034 patients, 748 (18.5%) initiated treatment via telehealth and 3286 (81.5%) in-person visits. Telehealth initiation was most common among patients aged 24-35 (25.0%) and least common among those aged 65+ (12.2%). Adjusted analyses found younger age (aOR: 1.54, 95% CI: 1.07-2.21 for ages 24-35 vs. 65+), prior telehealth use (aOR: 1.92, 1.55-2.37), cannabis use disorder (aOR: 1.38, 1.08-1.76), sedative use disorder (aOR: 1.63, 1.22-2.16), psychiatric/behavioral provider type (aOR: 2.38, 1.87-3.04), and zero comorbidities (aOR: 1.76, 1.33-2.34) as positively associated with telehealth initiation. Suburban (aOR: 0.73, 0.58-0.91) and urban (aOR: 0.77, 0.62-0.96) patients were less likely to initiate via telehealth compared with rural patients.
Conclusions:
Approximately 1 in 5 patients initiated buprenorphine via telehealth, with significant variation by age, geography, prior telehealth experience, comorbidity burden, and provider speciality. These findings underscore the need for postpandemic policies that preserve telehealth access although maintaining robust in-person treatment options to address diverse patient needs.
More Related Videos
07:13Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
07:48Intraoperative Video Consultation Following Bile Duct Transection Facilitates Direct OR Transfer for Robotic Hepaticojejunostomy at Tertiary Center
Published on: January 9, 2026
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Therapeutic Drug Monitoring: Affecting Factors
Factors Influencing Drug Absorption: Presystemic Elimination
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Drug Toxicity: Risk factors
Drug Dependence